Condition: Fibrolamellar Hepatocellular Carcinoma · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).
This description comes directly from the study's public registry record.
Colleen Apostal, RN · 410-614-3644 · GIClinicalTrials@jhmi.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins SKCCC | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06027086